| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 1g |
|
||
| 2g |
|
||
| 5g |
|
||
| 10g |
|
||
| Other Sizes |
|
| ln Vitro |
Pyrogallol (PG) is a reducing agent that is frequently employed as a photographic developer and in the hair dye business because it may produce free radicals, particularly superoxide anions (O2•-). Pyrogallol inhibits the development of Calu-6 and A549 lung cancer cells via depleting glutathione (GSH) and inducing apoptosis. Pyrogallol (PG) impacts mitogen-activated protein kinase (MAPK) and causes lung cancer cells to overproduce O2•-, which in turn causes apoptosis [1]. Investigations were conducted on the impact of pyrogallol on necrotic cell death and the survival of human lung fibroblasts (HPF). In these investigations, the level of inhibition or death of cell viability with or without a specific MAPK inhibitor was determined using 0, 50, or 100 µM pyrogallol. After 24 hours, treatment with 50 and 100 µM pyrogallol decreased HPF activity by roughly 40% and 65%, respectively. Treatment with a MEK inhibitor marginally increased, and treatment with a p38 inhibitor somewhat decreased, the suppression of cell viability in HPF cells treated with 50 µM pyrogallol. All MAPK inhibitors to some extent improved the inhibition of vitality in HPF cells treated with 100 µM pyrogallol; treatment with p38 inhibitor alone increased the viability of HPF control cells. Lactate dehydrogenase (LDH) release from cells was used to measure necrotic cell death. While LDH release from HPF cells was not affected by treatment with 50 µM pyrogallol, it was dramatically increased by treatment with 100 µM pyrogallol [1].
|
|---|---|
| References |
[1]. Han BR, et al. MAPK inhibitors enhance cell death in pyrogallol-treated human pulmonary fibroblast cells via increasing O2•- levels. Oncol Lett. 2017 Jul;14(1):1179-118
|
| Molecular Formula |
C6H6O3
|
|---|---|
| Molecular Weight |
126.111
|
| Exact Mass |
126.0317
|
| CAS # |
87-66-1
|
| SMILES |
OC1=C(O)C(O)=CC=C1
|
| Synonyms |
2,3-Dihydroxyphenol Benzene-1,2,3-triolPyrogallol C.I. 76515 NSC 5035Fouramine Brown AP
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 100 mg/mL (~792.96 mM)
H2O : ~50 mg/mL (~396.48 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (19.82 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (19.82 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (19.82 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 130 mg/mL (1030.85 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 7.9296 mL | 39.6479 mL | 79.2959 mL | |
| 5 mM | 1.5859 mL | 7.9296 mL | 15.8592 mL | |
| 10 mM | 0.7930 mL | 3.9648 mL | 7.9296 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
